Edwards Lifesciences (EW) Gross Margin (2009 - 2026)

Edwards Lifesciences' Gross Margin history runs 18 years deep, the most recent figure standing at 78.01% for Q1 2026.

• On a quarterly basis, Gross Margin fell 65.0% year-over-year to 78.01% in Q1 2026; TTM through Mar 2026 was 77.87%, a 163.0% decrease from a year earlier, with the FY2025 full-year figure at 78.01%, down 144.0% from the prior year.
• Gross Margin held at 78.01% in Q1 2026 per EW's latest filing, from 78.15% in the prior quarter.
• Across five years, Gross Margin topped out at 122.98% in Q4 2022 and bottomed at 77.52% in Q2 2025.
• The 5-year median for Gross Margin is 79.85% (2023), against an average of 81.86%.
• Across the five-year window, Gross Margin jumped 4626 bps in 2022 and tumbled 4280 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 122.98% in 2022, then plunged by 35 bps to 80.18% in 2023, then fell by 2 bps to 78.91% in 2024, then retreated by 1 bps to 78.15% in 2025, then dropped by 0 bps to 78.01% in 2026.
• Per Business Quant, the three latest EW Gross Margin figures stand at 78.01% (Q1 2026), 78.15% (Q4 2025), and 77.77% (Q3 2025).